Mazdutide
Also known as: IBI362
Mazdutide is a dual GLP-1 / glucagon receptor agonist licensed from Eli Lilly to Innovent Biologics for Greater China. Approved by China's NMPA in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes; NOT FDA-approved in the US.
Who's worth your money for Mazdutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 5 scored sellers
$109 · 6mg · 100.0% purity
Best value
Lowest $/mg among scored sellers
$79.99 · 10mg
Most tested
4 independent COAs on file
$810 · 6mg · 100.0% purity
Average price
$21.94/mg
Sellers
18
45-day trend
-26.3%
15 of 18 sellers have a current price· 4 stale hidden· 6 unverified hidden
Top Merit pick
🇺🇸 Profound Aminos95via Disclosed Labs · 23h ago
$18.17/mg -17.2% vs avg$109
6mg
- 🇺🇸 Hydro Research Peptides91
✓ verified at source · 23h ago
$135.00/mg +515.3% vs avg$810
6mg
- 🇺🇸 Peptidology89
✓ verified at source · 23h ago
$8.00/mg -63.5% vs avg$79.99
10mg
no purity - 🇺🇸 Certified Peptides61
✓ verified at source · 23h ago
$12.80/mg -41.7% vs avg$128
10mg
no purity - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · 23h ago
$23.10/mg +5.3% vs avg$231
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Mazdutide
Get one email when the market actually moves — no newsletter, no noise.
About Mazdutide
CAS
2259884-03-0
Molecular formula
C207H317N45O65
Typical dose range
2–10 mg subcutaneous once weekly (escalating regimen; approved maintenance doses in China 4.5–9 mg/week)
Half-life
~5–7 days (clinical PK: t1/2 range 174.8–1075.7 h across doses)
COAs for Mazdutide
12 third-party tests across 3 vendors. Each card links to the full report.
For
Mazdutide
by Ruo Bio· batch maz001
For
Mazdutide
by Profound Aminos· batch 2025-01-23
For
Mazdutide
by Profound Aminos· batch cmojb7xwe01f9kirx99syrvnd
For
Mazdutide
by Hydro Research Peptides· batch 2024-08-05
For
Mazdutide
by Optima Supply· batch 2024-08-05
For
Mazdutide
by Hydro Research Peptides· batch Mazdutide-6015
For
Mazdutide
by Optima Supply· batch Mazdutide-6027
For
Mazdutide
by Kimera Chems· batch KC-MAZ-RED1
For
Mazdutide
by Real Peptides· batch BATCH-0322
Purity not on file
For
Mazdutide
by Hydro Research Peptides· batch Mazdutide-6015
Purity not on file
For
Mazdutide
by Hydro Research Peptides· batch Mazdutide-6015
Purity not on file
For
Mazdutide
by Ruo Bio
20 citations indexed for Mazdutide
review · 2026
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis
Aim To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D).
Study · 2026
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
Importance Obesity is a worldwide problem and a major public health issue in China. Objective To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30).
review · 2026
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.
Study · 2026
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary
review · 2026
Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Introduction Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes.
Study · 2026